Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Butler

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal of the American College of Emergency Physicians Open|January 16, 2026
A Machine Learning Strategy to Predict the Number of High-Acuity Children Who Leave Without Being Seen From the Emergency DepartmentBrandon Kappy, Patrick Butler, Yiqi Su, et al.
Internal Medicine Journal|May 8, 2019
Safety and outcomes of <sup>177</sup> Lu-DOTATATE for neuroendocrine tumours: experience in New South Wales, AustraliaEnmoore Lin, Tina Chen, Alana Little, et al.
Big Data|January 2, 2015
Forecasting Significant Societal Events Using The Embers Streaming Predictive Analytics SystemAndy Doyle, Graham Katz, Kristen Summers, et al.
Optics Express|January 29, 2025
Linear field-resolved spectroscopy approaching ultimate detection sensitivityChristina Hofer, Daniel Bausch, Lukas Fürst, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2026
[<sup>177</sup>Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trialDavid L Chan, Katrin Marie Sjoquist, David Turner Ransom, et al.
The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The Lancet. Oncology|April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
Medrxiv : the Preprint Server for Health Sciences|January 3, 2024
Evaluation of FluSight influenza forecasting in the 2021-22 and 2022-23 seasons with a new target laboratory-confirmed influenza hospitalizationsSarabeth M Mathis, Alexander E Webber, Tomás M León, et al.
Nature Communications|July 26, 2024
Title evaluation of FluSight influenza forecasting in the 2021-22 and 2022-23 seasons with a new target laboratory-confirmed influenza hospitalizationsSarabeth M Mathis, Alexander E Webber, Tomás M León, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of the American College of Emergency Physicians Open|January 16, 2026
A Machine Learning Strategy to Predict the Number of High-Acuity Children Who Leave Without Being Seen From the Emergency DepartmentBrandon Kappy, Patrick Butler, Yiqi Su, et al.
Internal Medicine Journal|May 8, 2019
Safety and outcomes of <sup>177</sup> Lu-DOTATATE for neuroendocrine tumours: experience in New South Wales, AustraliaEnmoore Lin, Tina Chen, Alana Little, et al.
Big Data|January 2, 2015
Forecasting Significant Societal Events Using The Embers Streaming Predictive Analytics SystemAndy Doyle, Graham Katz, Kristen Summers, et al.
Optics Express|January 29, 2025
Linear field-resolved spectroscopy approaching ultimate detection sensitivityChristina Hofer, Daniel Bausch, Lukas Fürst, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2026
[<sup>177</sup>Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trialDavid L Chan, Katrin Marie Sjoquist, David Turner Ransom, et al.
The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The Lancet. Oncology|April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
Medrxiv : the Preprint Server for Health Sciences|January 3, 2024
Evaluation of FluSight influenza forecasting in the 2021-22 and 2022-23 seasons with a new target laboratory-confirmed influenza hospitalizationsSarabeth M Mathis, Alexander E Webber, Tomás M León, et al.
Nature Communications|July 26, 2024
Title evaluation of FluSight influenza forecasting in the 2021-22 and 2022-23 seasons with a new target laboratory-confirmed influenza hospitalizationsSarabeth M Mathis, Alexander E Webber, Tomás M León, et al.
Pageof 3